Trial intelligence / Profile preview

Non-Randomized Open-Label Study of 9-valent HPV Vaccine to Reduce HPV Infectivity

2021-005229-26Phase 4Active

Sponsor: Dr. Miguel Angel PavÃ³n Ribas
Start: Dec 2021
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 cohorts), sponsored by Dr. Miguel Angel PavÃ³n Ribas. Primary endpoint: Primary: In-vitro infectivity of HPV samples before and after vaccination. Started Dec 2021; status: active.

Drugs

recombinant human papillomavirus 9-valent vaccine

Conditions

human papillomavirus infection

Beyond the preview

Go deeper on 2021-005229-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2021-005229-26.